medicina60巻2号

2023年02月発行

特集 慢性疾患診療のお悩みポイントまとめました—高血圧からヘルスメンテナンスまで 消化器

GERD，消化性潰瘍，潰瘍予防で投与しているPPIはいつまで続ければいいですか？

著者： 木下慶一郎¹ 明保洋之¹

所属機関： ¹天理よろづ相談所病院総合内科

ページ範囲：P.354 - P.358

Point
◎プロトンポンプ阻害薬（PPI）の長期投与に関連する有害事象を把握し，漫然とPPIを投与しない．
◎軽症の胃食道逆流症（GERD）や非びらん性胃食道逆流症（NERD）に対するPPIは症状改善すれば中止，改善しない場合は酸逆流以外の病態を考える．
◎H. pylori潰瘍では除菌後にPPI中止，非ステロイド性抗炎症薬（NSAIDs）潰瘍では可能ならNSAIDsを止めて一定期間でPPIも中止する．
◎NSAIDs長期内服患者でもリスク因子がなければ，予防的PPIは不要である可能性あり．

参考文献

1）Lazarus B, et al：Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176：238-246, 2016

2）Zhang P, et al：Regular proton pump inhibitor use and incident dementia；Population-based cohort study. BMC Med 20：271, 2022

3）Yang YX, et al：Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296：2947-2953, 2006

4）Su T, et al：Meta-analysis；Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 53：27-36, 2018

5）Leonard J, et al：Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102：2047-2056, 2007

6）Xu HB, et al：Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients；A systematic review and meta-analysis. Genet Mol Res 14：7490-7501, 2015

7）Cao F, et al：Updated meta-analysis of controlled observational studies；Proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect 98：4-13, 2018

8）Cheungpasitporn W, et al：Proton pump inhibitors linked to hypomagnesemia；A systematic review and meta-analysis of observational studies. Ren Fail 37：1237-1241, 2015

9）Jung SB, et al：Association between vitamin B12 deficiency and long-term use of acid-lowering agents；A systematic review and meta-analysis. Intern Med J 45：409-416, 2015

10）Keszthelyi D, et al：Proton pump inhibitor use is associated with an increased risk for microscopic colitis；A case-control study. Aliment Pharmacol Ther 32：1124-1128, 2010

11）Xia B, et al：Regular use of proton pump inhibitor and the risk of inflammatory bowel disease；Pooled analysis of 3 prospective cohorts. Gastroenterology 161：1842-1852.e10, 2021

12）Aggarwal N：Drug-induced subacute gutaneous lupus erythematosus associated with proton pump inhibitors. Drugs Real World Outcomes 3：145-154, 2016

13）Vaezi MF, et al：Complications of proton pump inhibitor therapy. Gastroenterology 153：35-48, 2017

14）Freedberg DE, et al：The risks and benefits of long-term use of proton pump inhibitors；Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152：706-715, 2017

15）日本消化器病学会（編）：胃食道逆流症診療（GERD）診療ガイドライン2021（改訂第3版），南江堂，2021

16）Katz PO, et al：ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 117：27-56, 2022

17）Farrell B, et al：Deprescribing proton pump inhibitors；Evidence-based clinical practice guideline. Can Fam Physician 63：354-364, 2017

18）Aziz Q, et al：Functional esophageal disorders. Gastroenterology S0016-5085：00178-5, 2016

19）Fujiwara Y, Arakawa T：Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 44：518-534, 2009

20）Kaltenbach T, et al：Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 166：965-971, 2006

21）Harnik IG：In the Clinic. Gastroesophageal reflux disease. Ann Intern Med 163：ITC1, 2015

22）日本消化器病学会（編）：消化性潰瘍ガイドライン2020（改訂第3版），南江堂，2020

23）Sverdén E, et al：Peptic ulcer disease. BMJ 367：l5495, 2019

24）Laine L, et al：ACG clinical guideline；Upper gastrointestinal and ulcer bleeding. Am J Gastroenterol 116：899-917, 2021

nor aspirin/NSAID intake. Aliment Pharmacol Ther 38：946-954, 2013

26）Björnsson E, et al：Discontinuation of proton pump inhibitors in patients on long-term therapy；A double-blind, placebo-controlled trial. Aliment Pharmacol Ther 24：945-954, 2006

27）Inadomi JM, et al：Step-down management of gastroesophageal reflux disease. Gastroenterology 121：1095-1100, 2001